News

February 3, VIVA Pharm received marketing authorizations forCandesartan Viva Pharmdrug 8 mg (РК-ЛС-3№022747) and 16 mg (РК-ЛС-3№022748).

Candesartan Viva Pharm is a selective antagonist ofangiotensin II type 1receptors (AT1 receptors), which clinical efficacy and benefit in the treatment of arterial hypertension and reducing the risk of complications confirmed repeatedly.

The drug is indicated for use in arterial hypertension and chronic heart failure to reduce the mortality, rate of hospitalization and improve symptoms. It can be used both as a monotherapy and in combination with other antihypertensive agents. In patients with chronic heart failure (CHF) and reduction in LV systolic function (LVEF<40%), Candesartan reduces the peripheral vascular resistance and capillary pressure in the lungs, increases renin activity and concentrations of angiotensin II in the plasma, and decreases the aldoster one level.